In India the greatest need of public vs private patients would seem to be for burns. And that’s where BTM has the biggest impact. So I guess that’s where the biggest sales will be.
Having said that, I do recall reading a couple of years ago one of the first case reports from a surgeon in India about their private hospital treatment of a road accident victim with severe scalp injury.
As to MTX uptake and its effect on revenue per patient calculations, I think that it’s a case of wait and see.
I keenly await the patient numbers for H2. My wishful thinking is that the percentage increase will accelerate. The clinician snowball is growing dramatically if publications are any guide. Growing indications for use (the diversity is impressive) and geographical spread.
So I won’t be surprised if patient numbers grow dramatically too. In H2 and subsequently.
Swami has raised the flag of 1 million patients as a kind of standard around which to rally the troops (investors and employees). It will be more than interesting to see how long that takes to achieve.
The company has stated that MTX sales are not cannabalising sales of BTM in the US. So BTM sales should continue to grow along with, but eventually being outstripped by, sales of MTX (BTM will become “icing on the cake” of total revenues).
I imagine that the pricing of MTX, on a square centimetre basis, isn’t dramatically different to that of BTM. Does anyone have intel on this?
PNV Price at posting:
$1.50 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)